hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06381505, orgStudyIdInfo id: STUDY02002103, briefTitle: RetracTOR/ Retractor for Image Guided Trans-Oral Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Ryan J. Halter, class: OTHER, collaborators name: Dartmouth College, descriptionModule briefSummary: This study aims to demonstrate that a polymer retractor functions the same as a standard metal retractor used during endoscopy and throat surgery. The retractor is the device that holds the mouth open so the surgeon can easily access the mouth and throat. For example, this study aims to confirm that the mouth is held open the same amount with a polymer retractor as it is with a metal retractor. Benchtop experiments have demonstrated that the metal and polymer retractor's function the same, and thus this study will use this in patients., conditionsModule conditions: Oral Cavity Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Comparing intraoperative surgical working volume (SWV) of a radiolucent retractor (custom device) as compared to SWV of standard-of-care metal retractors., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dartmouth-Hitchcock Medical Center, city: Lebanon, state: New Hampshire, zip: 03756, country: United States, contacts name: Joseph Paydarfar, MD, role: CONTACT, phone: 603-650-8123, email: joseph.a.paydarfar@hitchcock.org, geoPoint lat: 43.64229, lon: -72.25176, hasResults: False
protocolSection identificationModule nctId: NCT06381492, orgStudyIdInfo id: 2024-0057, secondaryIdInfos id: A536130, type: OTHER, domain: UW- Madison, secondaryIdInfos id: SMPH/ORTHO&REHAB/PHYS THER, type: OTHER, domain: UW- Madison, secondaryIdInfos id: Protocol Version 11/20/2023, type: OTHER, domain: UW- Madison, briefTitle: Quantifying Patellar Tendon Microstructure Using DTI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: University of Wisconsin, Madison, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to understand how diffusion tensor imaging (DTI) relates to other traditional measures and knee function. The main question it aims to answer is:Will regions of known patellar tendon pathology present with smaller DTI scalar parameters, shorter fiber length, and lower fiber density compared to the contralateral tendon and healthy regions in the ipsilateral tendon.Participants will:* undergo MRI and ultrasound imaging* perform knee function test* complete questionnaires, conditionsModule conditions: Patellar Tendinopathy, conditions: Anterior Cruciate Ligament Reconstruction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: MRI, interventions name: Ultrasound (US), outcomesModule primaryOutcomes measure: Compare scalar parameters of known patellar tendon pathology to the contralateral tendon, primaryOutcomes measure: Compare DTI scalar parameters of known patellar tendon pathology to the healthy regions in the ipsilateral tendon, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Wisconsin - Madison, city: Madison, state: Wisconsin, zip: 53705, country: United States, contacts name: Maria Flory, role: CONTACT, phone: 608-262-8652, email: flory@ortho.wisc.edu, geoPoint lat: 43.07305, lon: -89.40123, hasResults: False
protocolSection identificationModule nctId: NCT06381479, orgStudyIdInfo id: B031, briefTitle: Exploring the Effects of Probiotics on Workplace Related Stress Symptoms, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-19, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: National Taiwan Sport University, class: OTHER, collaborators name: Bened Biomedical Co., Ltd., descriptionModule briefSummary: There is still a lack of research to explore the interaction between high-pressure workers and probiotics to improve the intestinal microbiota, sleep, inflammation and anti-oxidation. A total of 120 subjects are expected to be recruited and divided into two groups of 60 subjects, receiving probiotics or placebo, and completing a 8-week trial period., conditionsModule conditions: Stress, conditions: Sleep Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: probiotics, interventions name: placebo, outcomesModule primaryOutcomes measure: Cortisol, secondaryOutcomes measure: Perceived Stress Scale (PSS), secondaryOutcomes measure: Job Stress Scale, secondaryOutcomes measure: Overwork Survey, secondaryOutcomes measure: Insomnia Severity index (ISI), secondaryOutcomes measure: The State Trait Anxiety Inventory (STAI), secondaryOutcomes measure: Depression Anxiety Stress Scales (DASS-42), secondaryOutcomes measure: The Quality of Life, Enjoyment, and Satisfaction Questionnaire-16, QLESQ-16, secondaryOutcomes measure: VAS-GI, secondaryOutcomes measure: Patient Global Impression scales of Improvement rated by patient, PGI-C, secondaryOutcomes measure: Serotonin, secondaryOutcomes measure: GABA, secondaryOutcomes measure: Norepinephrine, secondaryOutcomes measure: Immunoglobulin A, IgA, secondaryOutcomes measure: adrenocorticotropic hormone, ACTH, secondaryOutcomes measure: Total Antioxidant Capacity, TAC, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Graduate Institute of Sports Science, National Taiwan Sport University, status: RECRUITING, city: Taoyuan, zip: 33301, country: Taiwan, contacts name: Chi-Chang Huang, PI, role: CONTACT, phone: +88633283201, phoneExt: 2409, email: john5523@ntsu.edu.tw, geoPoint lat: 24.95233, lon: 121.20193, hasResults: False
protocolSection identificationModule nctId: NCT06381414, orgStudyIdInfo id: ChildhoodEarlyOralAging, briefTitle: Childhood Early Oral Aging Syndrome: Prevalence, Etiological Factors, and Consequences on Occlusion, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-12-20, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: University of Nove de Julho, class: OTHER, descriptionModule briefSummary: The Early Oral Aging Syndrome (EOAS) is a broad concept concerning changes in oral health caused by systemic diseases of different origins, which are related to the current lifestyle in the pediatric population. Enamel defects associated with intrinsic and extrinsic factors promote the acceleration of dental structure loss in an early manner, causing impairment of function, aesthetics, and quality of life. In this context, this study aims to identify the prevalence of early childhood tooth wear and its severity using the Early Childhood Oral Aging Syndrome (EOAS) index as a diagnostic and epidemiological survey instrument, considering current alterations found in the pediatric population and verifying possible factors associated with each severity level. Participants aged 3 to 6 years old, enrolled in the pediatric dentistry clinic of the University Nove de Julho, will be selected. Children with imperfect amelogenesis and dentinogenesis, genetic syndromes, and undergoing orthodontic treatment will be excluded from the research. A questionnaire on general health, sleep quality, nutrition, hygiene habits, and parafunctional habits will be administered. Subsequently, a clinical examination will be conducted using the new Early Childhood Oral Aging Syndrome (EOAS) index with scores ranging from 0 to 3 to assess dental wear and dental management, and scores I to III that should be used concomitantly in cases of enamel defects presence, in addition to measuring the Vertical Dimension of Occlusion (VDO). EOAS scores will be computed and statistically analyzed for deciduous dentition with a significance level of P\<0.05., conditionsModule conditions: Aging, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 183, type: ESTIMATED, armsInterventionsModule interventions name: Observation, outcomesModule primaryOutcomes measure: Assessment of Tooth Wear and Dental Management, primaryOutcomes measure: Presence of Enamel Defects, primaryOutcomes measure: Vertical Dimension of Occlusion, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 6 Years, stdAges: CHILD, contactsLocationsModule locations facility: Nove de Julho University, city: São Paulo, state: SP, zip: 03155-000, country: Brazil, geoPoint lat: -23.5475, lon: -46.63611, hasResults: False
protocolSection identificationModule nctId: NCT06381388, orgStudyIdInfo id: NL86587.041.24, briefTitle: Interaction Between the Brain Hemispheres - Key to Motor Recovery After Stroke, acronym: InterAct, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2027-12-31, completionDateStruct date: 2028-06-30, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Jord Vink, class: OTHER, descriptionModule briefSummary: Rationale: Acute stroke leaves many patients with functional deficits, of which upper extremity motor impairment is one of the most disabling. Evidence from imaging and electrophysiological studies converge on the idea that impaired motor function after stroke is associated with disrupted network activity in the brain. Non-invasive brain stimulation methods, like transcranial magnetic stimulation (TMS), can be used to restore disrupted network activity and have been shown to successfully facilitate recovery of motor function in patients with stroke. Application of continuous theta burst stimulation (cTBS), an inhibitory form of TMS, to the contralesional motor cortex has been shown to improve the recovery of motor function in patients with stroke. However, responsiveness to this treatment varies considerably between stroke patients and the mechanisms through which contralesional cTBS facilitates recovery of motor function remain unclear.Objective: To determine if contralesional cTBS normalizes interhemispheric inhibition from the contralesional to ipsilesional primary motor cortex stroke patients with motor impairments. Age-matched healthy persons will serve as controls.Study design: A prospective, open-label within-subject intervention studyStudy population: 40 patients with first-ever ischemic stroke in one hemisphere and a unilateral paresis of the upper extremity, and 40 age-matched controls.Main endpoints: Primary endpoint: Interhemispheric inhibition from the contralesional to ipsilesional primary motor cortex. Secondary endpoints: contralesional intracortical inhibition; effect of contralesional TMS interference on finger tapping frequency., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: cTBS, outcomesModule primaryOutcomes measure: Interhemispheric inhibition (IHI), secondaryOutcomes measure: Ipsilesional resting motor threshold (RMT), secondaryOutcomes measure: Contralesional resting motor threshold (RMT), secondaryOutcomes measure: TMS interference, secondaryOutcomes measure: Intracortical inhibition (ICI), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: De Hoogstraat Revalidatie, city: Utrecht, country: Netherlands, contacts name: Anne Visser-Meily, MD, PhD, role: CONTACT, geoPoint lat: 52.09083, lon: 5.12222, hasResults: False
protocolSection identificationModule nctId: NCT06381375, orgStudyIdInfo id: 24-2-2024, briefTitle: Drug-drug Interactions With Anti-tuberculous Drugs, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2025-02-15, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: This study aims to assess the prevalence and the outcome of prescribing drugs known to have major drug-drug interactions with anti-tuberculous drugs among Kasr Alainy tuberculous patients., conditionsModule conditions: Drug-drug Interaction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: Anti Tuberculosis Drug, outcomesModule primaryOutcomes measure: Estimate the prevalence of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients, primaryOutcomes measure: 2. Assess the outcome of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients (response to treatment and the prevalence of life-threatening events)., eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Omnia Azmy Nabeh, status: RECRUITING, city: Cairo, zip: 11562, country: Egypt, contacts name: Omnia Azmy Nabeh, MD, role: CONTACT, phone: 01066969673, email: omnia.azmy@kasralainy.edu.eg, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06381362, orgStudyIdInfo id: IGOMIPS, briefTitle: Italian Registry of Minimally Invasive Pancreatic Surgery, acronym: IGOMIPS, statusModule overallStatus: RECRUITING, startDateStruct date: 2019-02-28, primaryCompletionDateStruct date: 2029-02-28, completionDateStruct date: 2029-02-28, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Associazione Italiana per lo Studio del Pancreas, class: OTHER, descriptionModule briefSummary: Assess the prevalence of minimally invasive pancreatic surgery in the country and its outcomes, conditionsModule conditions: Pancreatic Surgery, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 2300, type: ESTIMATED, armsInterventionsModule interventions name: Minimally invasive pancreatic surgery, outcomesModule primaryOutcomes measure: Postoperative short-term outcomes, primaryOutcomes measure: Long-term oncological outcomes, secondaryOutcomes measure: Rate of cases that after a minimally invasive approach had to be converted to and open approach, secondaryOutcomes measure: Surgeon learning curve, secondaryOutcomes measure: Surgeon learning curve, secondaryOutcomes measure: Surgeon learning curve, secondaryOutcomes measure: Surgeon learning curve, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Giovanni Capretti, status: RECRUITING, city: Milan, country: Italy, contacts name: Giovanni Capretti, Dr., role: CONTACT, phone: +390282247646, email: giovanni.capretti@hunimed.eu, contacts name: Alessandro Zerbi, Prof., role: PRINCIPAL_INVESTIGATOR, contacts name: Giovanni Capretti, Dr., role: SUB_INVESTIGATOR, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06381349, orgStudyIdInfo id: GPOEM-GEMS, briefTitle: Predicting Outcomes of GPOEM Using Gastric Electrical Mapping, acronym: GPOEM-GEMS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-05-01, completionDateStruct date: 2026-06-01, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Chris Varghese, class: OTHER, descriptionModule briefSummary: Gastric peroral endoscopic myotomy (GPOEM) is a minimally-invasive procedure that involves dividing the pylorus, to enhance gastric emptying in gastroparesis patients. This is a single-arm, multi-centre, prospective observational study to determine the clinical utility of Gastric Alimetry in predicting GPOEM treatment outcomes. The investigators further aim to develop a clinical decision rule to inform patient selection. Gastric Alimetry will be conducted \<1 month prior to GPOEM. All subjects will then be followed up for 12 months., conditionsModule conditions: Gastroparesis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Gastric Alimetry test, outcomesModule primaryOutcomes measure: Gastroparesis Cardinal Symptom Index (GCSI), secondaryOutcomes measure: Patient Assessment of Upper GastroIntestinal Disorders-Quality of Life (PAGI-QoL), secondaryOutcomes measure: EQ-5D scores, secondaryOutcomes measure: Patient assessment of upper gastrointestinal disorders-symptom severity index (PAGI-SYM), secondaryOutcomes measure: Patient Health Questionnaire - 8 (PHQ-8), secondaryOutcomes measure: Generalized Anxiety Disorder 7-item (GAD-7), secondaryOutcomes measure: Perceived Stress Scale 4 (PSS-4), secondaryOutcomes measure: Brief Illness Perception Questionnaire-Revised, secondaryOutcomes measure: Alimetry® Gut-Brain Wellbeing (AGBW), secondaryOutcomes measure: Work Productivity and Activity Impairment (WPAI), otherOutcomes measure: Change in Gastric Alimetry Phenotype, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06381323, orgStudyIdInfo id: PA2024, briefTitle: The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2027-03-01, completionDateStruct date: 2027-04-01, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, class: OTHER, descriptionModule briefSummary: The purpose of our research is to clarify the therapeutic efficacy and safety of Finerenone in patients with Primary Aldosteronism and explore the effective clinical predictive indicators of Finerenone in the treatment of Primary Aldosteronism., conditionsModule conditions: Primary Aldosteronism, conditions: Finerenone, conditions: Mineralocorticoid Receptor Antagonist, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 55, type: ESTIMATED, armsInterventionsModule interventions name: Finerenone, outcomesModule primaryOutcomes measure: 24h systolic BP drop value, secondaryOutcomes measure: The change of diastolic BP from the baseline level after Finerenone treatment, secondaryOutcomes measure: Hypertension remission rate, secondaryOutcomes measure: Change of serum potassium level, secondaryOutcomes measure: Change of plasma renin activity, secondaryOutcomes measure: Change of ARR, secondaryOutcomes measure: Change of UACR, secondaryOutcomes measure: Change of eGFR, otherOutcomes measure: Incidence of Treatment-Adverse Events as assessed by gynaecomastia, mastodynia, menstrual abnormalities, impotence, hyperkalemia and other adverse events., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Endocrinology, Drum Tower Hospital affiliated to Nanjing University Medical School, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210008, country: China, contacts name: Dalong Zhu, MD,PhD, role: CONTACT, phone: 86-25-83-105302, email: zhudalong@nju.edu.cn, contacts name: Ping Li, MD,PhD, role: CONTACT, phone: 86-25-83-105302, email: li78321@yeah.net, contacts name: Dalong Zhu, MD,PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Ping Li, MD,PhD, role: SUB_INVESTIGATOR, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06381297, orgStudyIdInfo id: OndokusMU, secondaryIdInfos id: Ondokuz Mayıs University, type: REGISTRY, domain: Clinical research ethics committee, briefTitle: Speech in Noise Discrimination Skills in Multiple Sclerosis Patients., statusModule overallStatus: COMPLETED, startDateStruct date: 2020-10-09, primaryCompletionDateStruct date: 2023-03-23, completionDateStruct date: 2023-04-23, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Asuman Kucukoner, class: OTHER, descriptionModule briefSummary: The aim of this clinical trial was to determine the effect of multiple sclerosis on speech reception and discrimination in noise and to compare the effects on the medial olivocochlear reflex, which is thought to affect speech intelligibility in noise, with a control group.The main questions it aims to answer are:Does MS disease affect the ability to discriminate speech in noise? Does MS affect contralateral suppression results assessing medial olivocochlear function? Is there a correlation between the ability to discriminate speech in noise and contralateral suppression skills of MS patients? Data from MS patients and healthy participants will be compared. Thirty relapsing remitting MS patients and 30 healthy participants admitted to the clinic will be evaluated., conditionsModule conditions: Multiple Sclerosis-Relapsing-Remitting, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: Multiple sclerosis patient group and healthy control group., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Hearing test, interventions name: Speech in noise discrimination test, interventions name: Montreal Cognitive Assessment Scale, interventions name: Symbol Number Modalities Test (SDMT), outcomesModule primaryOutcomes measure: Pure tone Audiometry Test, primaryOutcomes measure: Speech Audiometry, primaryOutcomes measure: Speech Discrimination in Noise Test, primaryOutcomes measure: Otoacoustic Emission Test, primaryOutcomes measure: Contralateral Suppression Test, secondaryOutcomes measure: Montreal Cognitive Assessment Scale, secondaryOutcomes measure: Symbol Digit Modalities Test, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ondokuz Mayıs University, city: Samsun, zip: 55300, country: Turkey, geoPoint lat: 41.27976, lon: 36.3361, hasResults: False